Mode
Text Size
Log in / Sign up

Meta-analysis of combination ambroxol and clenbuterol therapy for pediatric wheezing disorders shows improved outcomesKids Wheeze Less With New Combo Medicine

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note combination ambroxol and clenbuterol improves pediatric wheezing outcomes, with limited applicability outside China.

This meta-analysis synthesized evidence from 14 randomized controlled trials drawn from an initial evidence mapping of 227 RCTs. The scope focused on pediatric patients with wheezing disorders treated with combination therapy using ambroxol hydrochloride and clenbuterol hydrochloride oral solution compared to conventional treatment alone. The setting was predominantly China.

The overall response rate showed a relative risk of 1.26 with a 95% confidence interval of 1.10–1.44. The significant effective rate was higher with a relative risk of 1.55 and a 95% confidence interval of 1.36–1.76. Duration of symptoms was significantly reduced, including coughing with a mean difference of −1.40 (95% CI −1.75 to −1.06) and wheezing with a mean difference of −1.88 (95% CI −2.50 to −1.26). Other respiratory signs such as cough phlegm, wet lung sounds, and pulmonary rales also showed reductions. Length of hospital stay was significantly reduced with a mean difference of −1.13 (95% CI −1.45 to −0.82).

While the analysis reported that AHCHOS did not increase the risk of adverse events compared with conventional treatment alone, the authors noted that no definitive conclusions regarding safety could be drawn due to limited and inconsistent adverse event reporting. Serious adverse events and discontinuations were not reported.

All included studies were conducted in China, which may limit the generalizability of the findings to other populations. Additionally, the inconsistent adverse event reporting restricts the ability to fully assess the safety profile.

Imagine a child coughing through the night, waking up the whole family. The parents are tired, and the doctor visits feel endless. Now, imagine a treatment that helps the child breathe easier and go home sooner.

Wheezing disorders are common in children. They cause coughing, wheezing, and trouble breathing. These symptoms often keep kids out of school and disturb sleep.

Current treatments usually involve standard inhalers or steroids. While these help, some children do not get better fast enough. Families often worry about long hospital stays.

The surprising shift

Scientists in China looked at many studies to find a better way. They tested a specific liquid medicine called AHCHOS. This mix includes ambroxol hydrochloride and clenbuterol hydrochloride.

But here is the twist. This combination worked better than standard care alone. It helped children feel better faster without causing new problems.

What scientists didn't expect

Think of a clogged drain in your sink. Water backs up and flows slowly. Mucus in the lungs acts like that clog. It traps germs and makes breathing hard.

Standard medicine often just reduces inflammation. It is like turning down the heat on a fire. But this new medicine works differently. It acts like a powerful vacuum cleaner. It clears the mucus out of the airways.

When the mucus is gone, the air can flow freely. The child can breathe deeply again. This simple action solves the main problem quickly.

The study snapshot

Researchers searched many medical libraries for answers. They found 227 different studies. Most of these came from eastern China.

They picked the best 14 studies for a detailed review. These were strict tests where one group got the new medicine and another got standard care. The doctors watched the children closely for several weeks.

The results were clear. Children taking the new medicine improved more often. The chance of getting better was higher than with standard treatment alone.

Coughing stopped sooner. The wheezing sounds faded faster. Even the wet sounds in the lungs disappeared quicker. Most importantly, kids spent fewer days in the hospital.

On average, a child stayed in the hospital 1.13 fewer days. That is almost a full day saved for every child. This means less stress for parents and less cost for families.

This doesn't mean this treatment is available yet.

The catch

There is a limit to these findings. All the studies happened in China. This means we do not know if it works the same way in other countries.

Also, the reports on side effects were not very clear. We need more data to be sure it is safe everywhere.

This medicine is not available in every clinic today. It is still being studied. If you live in an area where this is used, talk to your doctor.

Do not stop current treatments without advice. Ask your pediatrician if this option fits your child's needs. Always follow the doctor's plan for your child's breathing.

More research is needed to confirm safety globally. Scientists will likely run new trials in different countries. This will help doctors decide if this should be a standard option.

Until then, the focus remains on clearing airways and getting kids home safely. Every day saved in the hospital is a win for a family.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo evaluate the efficacy and safety of ambroxol hydrochloride and clenbuterol hydrochloride oral solution (AHCHOS) in pediatric patients with wheezing disorders and provide a comprehensive evidence map of the current clinical status.MethodsA literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, Wanfang, and CBM to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of AHCHOS in children with wheezing disorders. The clinical status was descriptively summarized. Meta-analyses for efficacy and safety outcomes were performed using a random-effects model in Review Manager 5.4. Outcomes were treatment effectiveness, times to symptom and clinical sign resolution, length of hospital stay, and adverse events (AEs). All time-related outcomes were reported in days.ResultsA total of 227 RCTs were included in the evidence mapping, 14 of which met the criteria for meta-analysis. Evidence mapping revealed a general increase in the number of studies from 2005 to a peak in 2012, followed by a decline. Most studies were conducted in eastern China, particularly in Henan Province. Meta-analysis results demonstrated that combination therapy with AHCHOS significantly improved the overall response rate [risk ratio (RR) 1.26, 95% confidence interval (CI) 1.10–1.44] and significant effective rate (RR 1.55, 95% CI 1.36–1.76). It also significantly reduced the duration (days) of coughing [mean difference (MD) −1.40, 95% CI −1.75 to −1.06], wheezing (MD −1.88, 95% CI −2.50 to −1.26), cough phlegm (MD −2.00, 95% CI −2.76 to −1.24), wet lung sounds (MD −1.82, 95% CI −2.33 to −1.30), pulmonary rales (MD −2.27, 95% CI −2.90 to −1.64), and hospital stay (MD −1.13, 95% CI −1.45 to −0.82). Furthermore, AHCHOS did not increase the risk of AEs compared with conventional treatment alone.ConclusionCombination therapy with AHCHOS was associated with modest but statistically significant improvements in symptom resolution and length of hospital stay compared with conventional treatment alone. However, all included studies were conducted in China, which may limit the generalizability of the findings. In addition, no definitive conclusions regarding safety could be drawn due to limited and inconsistent adverse event reporting. Further safety assessments in future trials are warranted.Systematic Review RegistrationThe protocol has been registered on INPLASY (INPLASY202480121).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.